These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 16942864

  • 1. Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea.
    Lee DG, Choi SM, Shin WS, Lah HO, Yim DS.
    Int J Antimicrob Agents; 2006 Oct; 28(4):333-9. PubMed ID: 16942864
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E, Konkoly-Thege M, Kuti JL, Nicolau DP.
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [Abstract] [Full Text] [Related]

  • 8. Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy.
    Santos Filho L, Eagye KJ, Kuti JL, Nicolau DP.
    Clin Microbiol Infect; 2007 Jun; 13(6):579-85. PubMed ID: 17331121
    [Abstract] [Full Text] [Related]

  • 9. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
    Lodise TP, Nau R, Kinzig M, Drusano GL, Jones RN, Sörgel F.
    J Antimicrob Chemother; 2007 Nov; 60(5):1038-44. PubMed ID: 17785282
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y, Kobayashi Y.
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [Abstract] [Full Text] [Related]

  • 13. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia.
    Jaruratanasirikul S, Limapichat T, Jullangkoon M, Aeinlang N, Ingviya N, Wongpoowarak W.
    Int J Antimicrob Agents; 2011 Sep; 38(3):231-6. PubMed ID: 21726984
    [Abstract] [Full Text] [Related]

  • 14. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients.
    Li C, Kuti JL, Nightingale CH, Nicolau DP.
    J Clin Pharmacol; 2006 Oct; 46(10):1171-8. PubMed ID: 16988206
    [Abstract] [Full Text] [Related]

  • 15. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.
    Kuti JL, Horowitz S, Nightingale CH, Nicolau DP.
    Pharmacotherapy; 2005 Jul; 25(7):935-41. PubMed ID: 16006272
    [Abstract] [Full Text] [Related]

  • 16. Population pharmacokinetics of meropenem in burn patients.
    Doh K, Woo H, Hur J, Yim H, Kim J, Chae H, Han S, Yim DS.
    J Antimicrob Chemother; 2010 Nov; 65(11):2428-35. PubMed ID: 20817742
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF, Bulitta J, Lipman J, Kirkpatrick CM.
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [Abstract] [Full Text] [Related]

  • 18. Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections.
    Kuti JL, Ong C, Lo M, Melnick D, Soto N, Nicolau DP.
    Int J Antimicrob Agents; 2006 Jul; 28(1):62-8. PubMed ID: 16759839
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.
    Lomaestro BM, Drusano GL.
    Antimicrob Agents Chemother; 2005 Jan; 49(1):461-3. PubMed ID: 15616337
    [Abstract] [Full Text] [Related]

  • 20. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
    Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP.
    J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.